16/10/2018
Speakers will call for Europe to continue their commitment to building a sustainable, circular bioeconomy.
11/10/2018
EuropaBio is pleased to welcome the publication of an updated EU Bioeconomy Strategy.
11/10/2018
29/06/2018
A EuropaBio white paper calling for: equal assessment transparency; equal measures for traceability and adverse event reporting; and a level playing field for market access.
28/06/2018
The Pharmaceutical Industry generally welcomes the European Commission’s Proposal for a Regulation on HTA.
25/06/2018
The economic impact of the biotech sector today and beyond.
28/05/2018
As an association that has manufacturers of both originator and biosimilar medicines as members, EuropaBio strongly doubts that the promises of today’s Commission proposal outweigh the risks of losing investment in new medicines.
31/03/2018
The associations representing the European and British life science industry have today responded to the European Council approving terms of the transition period agreed between the UK Government and EU.
31/03/2018
The European Health Community has warned that time is running out to secure patients’ interests in Brexit negotiations. With Phase 2 of the negotiations looming, health groups across Europe have drawn up a list of crucial unanswered questions that must be answered by the EU and UK negotiators to ‘put patients first’ in the negotiations.
28/12/2017
The life science industry is highly integrated across Europe and regulated under EU law through a sophisticated system of legal and regulatory arrangements involving EU Institutions, MS and national competent authorities.
28/12/2017
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit the European Union.
29/11/2017
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
30/10/2017
Wealth of innovation on display at annual showcase event demonstrates Europe’s strong response to SDG challenges and potential of the circular bioeconomy.
28/10/2017
The system of IP rewards and incentives exists and works together to allow adequate
time for the companies and investors to recoup their years of investment and fully realise clinical value before their inventions become part of the public domain and can be used by others.
27/09/2017
Possible solutions to improve the European regulatory procedures for clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms
06/06/2017
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
27/05/2017
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
03/03/2017
EuropaBio notes the adoption by the European Parliament of the report on EU options for improving patient access to medicines on 2 March 2017, in Brussels.
02/02/2017
This paper proposes key steps to consider when purchasing biological medicines, looking at each stage of the procurement process.
23/01/2017
European Commission Initiative Improves Information for Patients on Biosimilar Medicines.